Primary glomerulonephritis (CKD Stage 3)
Conditions
Interventions
Sponsors
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 70 years, gender: male or female; 2.In line with the Western medical diagnostic criteria for chronic kidney disease,patients with CKD grade 3(eGFR>30-59 ml / min / 1.73m^2) according to the K / DOQI recommended grading criteria for renal impairment and who had renal biopsy pathological data of glomerulonephritis (CKD grade 3).The EPI formula as follows: eGFR=ax(Scr/b)^Cx0.993^Age(a values were taken separately according to gender as follows, male = 141 female = 144; The b values are taken as follows depending on gender, male = 0.9 female = 0.7; The c value takes the following values based on age and size of serum creatinine, respectively, for men: serum creatinine 0.7 mg / dl = -1.209 for women: serum creatinine 0.7 mg / dl = -1.209); 3.Blood pressure control = 100 mmHg and DBP >= 60 mmHg; 4.Severe infections, water, electrolyte and acid-base balance disorders are effectively controlled, and serum potassium is within the normal range; 5.Testing after 2 weeks of the lead-in period was eligible for patients with GFR: 30-59 ml / min / 1.73m^2 and BP <= 140 / 90 mmHg(patients are taking calcium antagonists, diuretics, and sympathetic nerve suppression do not need to enter the lead-in period); 6.Volunteered to participate in the clinical study and agreed to sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with severe primary diseases including heart, brain, liver and hematopoietic system need prompt treatment; 2.24-hour urine protein quantification 2.0 g; 3.Hb <=100g/L; 4.Patients have had hemodialysis or peritoneal dialysis in the past; 5.Secondary renal diseases such as diabetic nephropathy or multiple myeloma should be excluded; 6.Patients were participating in other clinical trials of drugs or had participated in other clinical trials within 3 months or had used western glucocorticoids, immunosuppressive agents, Tripterygium wilfordii preparations; 7.Patients had taken other traditional Chinese medicines for nearly 2 weeks, which might affect the judgment of efficacy, can only be selected after two weeks of elution; 8.If the patients have used angiotensin-converting enzyme inhibitors, or angiotensin receptor antagonists, they need to wash out 2 weeks before for being selected; 9.Pregnant or lactating women; 10.Allergic to drugs and their ingredients involved in this study; 11.Patients with a previous history of hypotension; 12.Patients with bilateral renal artery stenosis; 13.Suspected or true history of alcohol or drug abuse; 14.Patients after kidney transplantation, tumor or mental illness; 15.The investigator believes that it is not suitable for participating in clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in glomerular filtration rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary transforming growth factor -ß1 is a specific indicator of renal fibrosis;Cystatin C;Urea nitrogen;Change value of ß2 microglobulin;Change in glomerular filtration rate;Change value of urine protein quantification at 24h;Blood lipid changes after treatment;Change value of serum creatinine;Traditional Chinese Medicine symtom score;Hemoglobin;Blood uric acid; | — |
Countries
China
Contacts
Public ContactTao Yanyan
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed